FDA Issues ‘High Risk’ Safety Alert for Radiology Device After 5 Serious Injuries

Why It Matters

The alert exposes a serious patient‑safety hazard that could disrupt interventional radiology procedures and force hospitals to reassess device inventories. It also underscores regulatory scrutiny that can affect confidence in niche medical‑device manufacturers.

Key Takeaways

• Erbe's flexible cryoprobes may rupture due to insufficient adhesive.
• Rupture can cause loud noise, tinnitus, or hearing loss.
• Five serious injuries reported; no deaths as of Feb 24.
• Impacted lot numbers contain 90,034 units, 43 complaints filed.
• Erbe improved manufacturing, added inspections, and halted affected lots.

Pulse Analysis

Flexible cryoprobes are a cornerstone of minimally invasive radiology, enabling clinicians to freeze and extract tumors, biopsies, and obstructive tissue. Their precision and rapid action have made them indispensable in operating rooms worldwide. The recent FDA safety alert, however, reveals a manufacturing flaw—insufficient adhesive—that can cause the probe to burst under pressure. When this occurs, the sudden release of energy generates a deafening pop, exposing patients and staff to acoustic trauma and potential burns. The incident underscores how even highly specialized devices can harbor latent risks that surface only after widespread clinical use.

From a regulatory standpoint, the FDA’s high‑risk classification signals heightened vigilance and may trigger broader industry reviews of quality‑assurance protocols. Manufacturers are now compelled to revisit adhesive application processes, implement additional inspection checkpoints, and document corrective actions to satisfy both the agency and healthcare providers. Hospitals receiving the recall must swiftly identify affected inventory, halt procedures involving the compromised lots, and communicate risks to clinical teams. This scenario illustrates the importance of robust post‑market surveillance systems that can capture adverse events early and trigger rapid response mechanisms.

Erbe’s response—recalling over 90,000 units, enhancing manufacturing controls, and issuing detailed guidance—aims to restore confidence among clinicians and regulators. The episode serves as a cautionary tale for the broader medical‑device sector, emphasizing that supply‑chain integrity and meticulous production oversight are non‑negotiable in high‑stakes clinical environments. As the FDA continues its review, the industry will likely see tighter standards for adhesive bonding and more frequent audits, driving a shift toward greater transparency and patient safety across interventional radiology tools.